Pathology - Research and Practice, Journal Year: 2025, Volume and Issue: 269, P. 155864 - 155864
Published: March 1, 2025
Language: Английский
Biomedicines, Journal Year: 2024, Volume and Issue: 12(1), P. 201 - 201
Published: Jan. 16, 2024
Globally, malignancies cause one out of six mortalities, which is a serious health problem. Cancer therapy has always been challenging, apart from major advances in immunotherapies, stem cell transplantation, targeted therapies, hormonal precision medicine, and palliative care, traditional therapies such as surgery, radiation therapy, chemotherapy. Natural products are integral to the development innovative anticancer drugs cancer research, offering scientific community possibility exploring novel natural compounds against cancers. The role like Vincristine Vinblastine thoroughly implicated management leukemia Hodgkin’s disease. computational method initial key approach drug discovery, among various approaches. This review investigates synergy between techniques, highlights their significance discovery process. transition experimental validation highlighted through vitro vivo studies, with examples betulinic acid withaferin A. path toward therapeutic applications have demonstrated clinical studies silvestrol artemisinin, preclinical investigations trials. article also addresses challenges limitations potential anti-cancer drugs. Moreover, integration deep learning artificial intelligence methods may be useful for enhancing products.
Language: Английский
Citations
81
Frontiers in Cell and Developmental Biology, Journal Year: 2025, Volume and Issue: 12
Published: Jan. 7, 2025
The advent of immune checkpoint inhibitors (ICIs) in colorectal cancer (CRC) treatment marks a major breakthrough. These therapies have proven safer and more effective than traditional radiotherapy targeted treatments. Immunotherapies like pembrolizumab, nivolumab, ipilimumab pioneered new avenues, potentially improving patient outcomes quality life. Additionally, advances immunotherapy prompted detailed research into CRC therapies, especially those integrating ICIs with conventional treatments, providing hope for patients shaping future practice. This review delves the mechanisms various evaluates their therapeutic potential when combined radiotherapy, chemotherapy, clinical settings. It also sheds light on current application involving treatment.
Language: Английский
Citations
2
Cancer Immunology Immunotherapy, Journal Year: 2025, Volume and Issue: 74(5)
Published: April 1, 2025
Language: Английский
Citations
2
Journal of Molecular Medicine, Journal Year: 2024, Volume and Issue: 102(8), P. 987 - 1000
Published: June 27, 2024
Language: Английский
Citations
13
Nature Immunology, Journal Year: 2024, Volume and Issue: 25(10), P. 1793 - 1808
Published: Sept. 16, 2024
Language: Английский
Citations
10
Diseases, Journal Year: 2025, Volume and Issue: 13(1), P. 24 - 24
Published: Jan. 20, 2025
Background: Cancer remains a leading cause of morbidity and mortality worldwide. Traditional treatments like chemotherapy radiation often result in significant side effects varied patient outcomes. Immunotherapy has emerged as promising alternative, harnessing the immune system to target cancer cells. However, complexity responses tumor heterogeneity challenges its effectiveness. Objective: This mini-narrative review explores role artificial intelligence [AI] enhancing efficacy immunotherapy, predicting responses, discovering novel therapeutic targets. Methods: A comprehensive literature was conducted, focusing on studies published between 2010 2024 that examined application AI immunotherapy. Databases such PubMed, Google Scholar, Web Science were utilized, articles selected based relevance topic. Results: significantly contributed identifying biomarkers predict immunotherapy by analyzing genomic, transcriptomic, proteomic data. It also optimizes combination therapies most effective treatment protocols. AI-driven predictive models help assess response guiding clinical decision-making minimizing effects. Additionally, facilitates discovery targets, neoantigens, enabling development personalized immunotherapies. Conclusions: holds immense potential transforming related data privacy, algorithm transparency, integration must be addressed. Overcoming these hurdles will likely make central component future offering more treatments.
Language: Английский
Citations
1
Oncology Letters, Journal Year: 2025, Volume and Issue: 29(3)
Published: Jan. 22, 2025
Adenoid cystic carcinoma (ACC) of the salivary glands is second most common type gland cancer, and characterized by a poor prognosis an unclear pathology. The incidence ACC rare, as it accounts for 10-15% all tumors affects mainly patients aged between 50 60 years. annual rate estimated to be ~4.5 cases per 100,000 individuals. Due its rarity use contaminated cell lines in previous investigations, precise etiological factors underlying remain poorly understood. Current treatment modalities, typically involving surgery with or without postoperative radiotherapy, often prove unsatisfactory due potential local recurrence delayed distant metastases, which may manifest 3-5 years after constitute primary failure existing therapeutic approaches. indolent growth pattern, along perineural perivascular invasion, potentially responsible onset metastases. No effective systemic therapy has been established so far. Therefore, management represents significant challenge. Exploring molecular characteristics ACC, including reasons behind propensity invasion correlation immune system, offers promising strategies managing could open up novel pathways future interventions. Currently, immunotherapy shown limited effectiveness. While exact mechanism lack response remains unknown, low levels tumor-infiltrating lymphocytes these contribute this resistance. identifying targets enhance against tumor cells essential. present review provides update on clinical studies explores that ACC.
Language: Английский
Citations
1
Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15
Published: April 4, 2024
Immunotherapy has been developed, which harnesses and enhances the innate powers of immune system to fight disease, particularly cancer. PD-1 (programmed death-1) PD-L1 death ligand-1) are key components in regulation system, context cancer immunotherapy. regulated by PTMs, including phosphorylation, ubiquitination, deubiquitination, acetylation, palmitoylation glycosylation. PROTACs (Proteolysis Targeting Chimeras) a type new drug design technology. They specifically engineered molecules that target specific proteins within cell for degradation. have designed demonstrated their inhibitory activity against PD-1/PD-L1 pathway, showed ability degrade proteins. In this review, we describe how improve efficacy could be novel strategy combine with radiotherapy, chemotherapy immunotherapy patients.
Language: Английский
Citations
6
World Journal of Biology Pharmacy and Health Sciences, Journal Year: 2024, Volume and Issue: 17(2), P. 068 - 079
Published: Feb. 9, 2024
This review provides a comprehensive analysis of the progress made in cancer research within United States. Over past few decades, significant strides have been taken to understand complexities cancer, leading breakthroughs diagnostics, treatment modalities, and overall patient care. The explores key themes, including advancements genomic medicine, immunotherapy, personalized approaches. Advancements medicine emerged as cornerstone research, allowing for deeper understanding genetic basis various cancers. integration precision techniques has facilitated identification specific mutations, paving way targeted therapies tailored individual patients. Genomic profiling not only enhanced diagnostic accuracy but also provided valuable insights into heterogeneity, guiding researchers toward more effective strategies. Immunotherapy revolutionized by harnessing body's immune system target eliminate cells. delves remarkable developing checkpoint inhibitors, adoptive cell therapies, vaccines. These innovations shown unprecedented success treating previously challenging malignancies, offering new hope patients with advanced-stage concept is further explored, emphasizing shift from one-size-fits-all approach tailoring treatments based on characteristics. advent liquid biopsies advanced imaging enabled real-time monitoring responses, facilitating timely adjustments improving outcomes. Despite these advancements, acknowledges persistent challenges, such need collaboration between institutions, imperative increased funding, importance addressing healthcare disparities ongoing commitment interdisciplinary translational initiatives, patient-centered emphasized essential overcoming challenges propelling field USA. In conclusion, this paints picture insights, immunotherapeutic breakthroughs, approaches underscores promising future patients, while acknowledging necessity continued efforts address existing propel even greater advancements.
Language: Английский
Citations
5
Clinical Oncology, Journal Year: 2024, Volume and Issue: 36(10), P. e408 - e419
Published: July 2, 2024
Language: Английский
Citations
5